Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | STK17B | O94768 | 1/20 | 0.35 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | GRK6 | P43250 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | EEF2K | O00418 | 1/20 | 0.32 |
| ▸ | MMP12 | P39900 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2917019 | 0.80 | PTGES (0.35) | HTTGAAKDM4EMAPTL3MBTL1 | |
| SCHEMBL2910386 | 0.74 | TOP2A (0.37) | CYP19A1 | |
| SCHEMBL5891827 | 0.69 | CYP19A1 (0.36) | CYP19A1 | |
| SCHEMBL9090439 | 0.69 | CYP19A1 (0.55) | CYP19A1MMP12MMP13 | |
| SCHEMBL9090407 | 0.68 | CYP19A1 (0.62) | CYP19A1 | |
| SCHEMBL9089515 | 0.65 | CYP19A1 (0.64) | CYP19A1EPHX2 | |
| SCHEMBL9092376 | 0.65 | CYP19A1 (0.55) | CYP19A1EPHX2 | |
| SCHEMBL9016828 | 0.63 | SLC6A3 (0.51) | GAAMAPT | |
| SCHEMBL9092229 | 0.63 | CYP19A1 (0.56) | CYP19A1EPHX2 | |
| SCHEMBL2577670 | 0.63 | SLC6A3 (0.65) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076327-B2 | Condensed imidazole derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2011-12-13 | — | — | US | disclosed |
| US-20100305110-A1 | CONDENSED IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| US-7799780-B2 | Condensed imidazole derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| EP-2004657-B1 | CONDENSED IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-09-01 | — | — | EP | disclosed |
| US-20090012068-A1 | Condensed Imidazole Derivatives as Aldosterone Synthase Inhibitors | NOVARTIS AG (CH) | 2009-01-08 | — | — | US | disclosed |
| EP-2004657-A1 | CONDENSED IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | Speedel Experimenta AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007116097-A1 | CONDENSED IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012068-A1 | Condensed Imidazole Derivatives as Aldosterone Synthase Inhibitors | CYP11B1, CYP11B2, REN | HTT 4809/4885GAA 2513/4885KDM4E 3544/4885 |
| US-20100305110-A1 | CONDENSED IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | CYP11B1, CYP11B2, REN | HTT 4813/4885GAA 2535/4885KDM4E 3583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.